Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

151.07 +3.86 (+2.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,946,296
Open 146.72
Bid (Size) 148.90 (100)
Ask (Size) 149.99 (100)
Prev. Close 147.21
Today's Range 145.29 - 151.43
52wk Range 34.00 - 155.70
Shares Outstanding 106,313,250
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Revolution (RVMD) Q1 2026 Earnings Transcript ↗
Revolution (RVMD) Q1 2026 Earnings Transcript 
Via The Motley Fool
Revolution Medicines Inc (NASDAQ:RVMD) Q1 2026 Loss Widens Amid Clinical Promise ↗
Via Chartmill

Performance

YTD
+91.2%
+91.2%
1 Month
+58.4%
+58.4%
3 Month
+56.5%
+56.5%
6 Month
+154.6%
+154.6%
1 Year
+303.5%
+303.5%

More News

Read More
News headline image
Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It Seems ↗
Via The Motley Fool
News headline image
Revolution Medicines (RVMD): The New Titan of the RAS Pathway (2026 Research Feature)
Via Finterra
Topics Initial Public Offering
News headline image
The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
What's going on in today's session ↗
Via Chartmill
News headline image
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Which stocks are moving before the opening bell on Monday? ↗
Via Chartmill
News headline image
Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
From Revolution Medicines, Inc.
Via GlobeNewswire
News headline image
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗
Via The Motley Fool
News headline image
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Derivatives ETFs Regulatory Compliance
News headline image
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗
Via The Motley Fool
News headline image
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗
Via The Motley Fool
News headline image
Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗
Via The Motley Fool
News headline image
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Revolution Medicines, Inc. - Common Stock publicly traded?
Yes, Revolution Medicines, Inc. - Common Stock is publicly traded.
What exchange does Revolution Medicines, Inc. - Common Stock trade on?
Revolution Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Revolution Medicines, Inc. - Common Stock?
The ticker symbol for Revolution Medicines, Inc. - Common Stock is RVMD on the Nasdaq Stock Market
What is the current price of Revolution Medicines, Inc. - Common Stock?
The current price of Revolution Medicines, Inc. - Common Stock is 151.07
When was Revolution Medicines, Inc. - Common Stock last traded?
The last trade of Revolution Medicines, Inc. - Common Stock was at 05/06/26 04:00 PM ET
What is the market capitalization of Revolution Medicines, Inc. - Common Stock?
The market capitalization of Revolution Medicines, Inc. - Common Stock is 16.06B
How many shares of Revolution Medicines, Inc. - Common Stock are outstanding?
Revolution Medicines, Inc. - Common Stock has 16B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.